Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

FIT Biotech and ImmunoVaccine Ally to Enhance HIV Vaccine Candidate

FIT’s DNA plasmid will be combined with IVT’s delivery platform. FIT Biotech and ImmunoVaccine Technologies (IVT) entered a preclinical research partnership to combine FIT’s anti-HIV DNA plasmid with IVT’s vaccine delivery system, DepoVax. GTU MiltiHIV is a sy

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

FIT’s DNA plasmid will be combined with IVT’s delivery platform.

FIT Biotech and ImmunoVaccine Technologies (IVT) entered a preclinical research partnership to combine FIT’s anti-HIV DNA plasmid with IVT’s vaccine delivery system, DepoVax. GTU MiltiHIV is a synthetic DNA plasmid that covers the antigenic variability within HIV strains, attempting to counteract HIV’s known ability to mutate rapidly and therefore avoid effective vaccine therapy.

“DepoVax will act as a vector to deliver FIT Biotech’s GTU MultiHIV DNA vaccine, and our goal is to develop a more sophisticated and efficient HIV vaccine candidate,” says Marc Mansour, Ph.D., vp of R&D at IVT. DepoVax is a vaccine delivery system that delivers DNA plasmids into lymph nodes using liposomes to encapsulate a target antigen.

♦♦♦ Related News from IVT La Jolla Institute to Test IVT’s Delivery Platform with Infectious Disease Candidates (Mar. 27, 2009) ImmunoVaccine Technologies Receives Funding to Further Cancer and Infectious Disease Vaccine Development (Jan. 21, 2008) ImmunoVaccine Technologies to Take Over Immunotope (Dec. 10, 2007)

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Why We Need an HIV Vaccine

There are many treatments for HIV , but it's still important to develop vaccines. HIV drugs have side effects, are expensive, and can be hard for people in some countries to get. You can also develop a problem called "drug resistance," which means you'll need to switch to new medications when the ones you're using stop working well for you. There are steps you can take to reduce your risk of HIV. These include: Lower the number of people you have sex with. Use a condom when you have sex. Take medicine every day called pre-exposure prophylaxis (PrEP), such as emtricitabine/tenofovir disoproxil fumarate ( Truvada ) or emtricitabine/tenofovir alafenamide ( Descovy ). Even so, thousands of people in the U.S. each year are diagnosed with HIV. An HIV vaccine could help prevent HIV infection and save lives.

Source: www.webmd.com ↗
02What Other Drugs Interact with HIV Vaccine?

If your doctor has directed you to use this medication, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

Source: www.rxlist.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →